Cynthia Elliott, MD
Rheumatology · Lawrenceville, GANPI 1720036957
Payments from drug & device makers
Across 1,004 payments — averaging $100.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$34K
- Boehringer Ingelheim$11K
- AbbVie$9K
- Sanofi$8K
- UCB, Inc.$8K
- Mallinckrodt Enterprises LLC$8K
- plus $22K from 33 others
Across 9 payments — averaging $234.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$2K
What the payments were for
- Consulting fees$54,11664%
- Travel & lodging$8,22510%
- Food & beverage$21,28625%
- Education$3850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 149 | $34,409 |
| Boehringer Ingelheim | 29 | $11,344 |
| AbbVie | 308 | $9,395 |
| Sanofi | 26 | $8,344 |
| UCB, Inc. | 21 | $7,692 |
| Mallinckrodt Enterprises LLC | 13 | $7,669 |
| Johnson & Johnson | 64 | $6,915 |
| E.r. Squibb & Sons, L.L.C. | 40 | $2,552 |
| Sobi, Inc | 6 | $2,327 |
| Amgen(2 entities) | 124 | $2,062 |
| Astrazeneca UK Limited | 11 | $1,702 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $1,493 |
| Lilly USA, LLC | 34 | $802 |
| Pfizer | 43 | $742 |
| Aurinia Pharma U.S., Inc. | 24 | $671 |
| Mallinckrodt Hospital Products Inc. | 23 | $592 |
| Janssen Scientific Affairs, LLC | 6 | $342 |
| Sanofi-aventis U.S. LLC | 4 | $314 |
| Medexus Pharma, Inc. | 12 | $263 |
| GSK | 10 | $248 |
| AstraZeneca(2 entities) | 8 | $228 |
| ANI Pharmaceuticals, Inc. | 6 | $170 |
| Grifols USA, LLC | 5 | $99 |
| Janssen Research & Development, LLC | 3 | $82 |
| Sandoz | 4 | $81 |
| Actelion Pharmaceuticals US, Inc. | 3 | $51 |
| Organon | 2 | $48 |
| Merck | 2 | $37 |
| Fresenius Kabi USA, LLC | 2 | $37 |
| Genentech USA, Inc. | 2 | $33 |
| Zyla Life Sciences, Inc. | 2 | $31 |
| Ultragenyx Pharmaceutical Inc. | 2 | $29 |
| Bristol Myers Squibb | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Biocon Biologics Inc | 1 | $21 |
| Mylan Institutional Inc. | 1 | $16 |
| Radius Health, Inc. | 1 | $15 |
| Octapharma USA, Inc. | 1 | $13 |
| Eli Lilly | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$100,920 in reported general payments places this provider in the 85th percentile of 177 rheumatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 48 | $435,243 |
| RinvoqUpadacitinib | 43 | $290,662 |
| Cosentyx Sensoready PenSecukinumab | 12 | $186,845 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 25 | $186,346 |
| Humira(Cf) PenAdalimumab | 23 | $159,853 |
| Xeljanz XrTofacitinib Citrate | 19 | $108,133 |
| BenlystaBelimumab | 23 | $106,603 |
| Humira(Cf)Adalimumab | 13 | $104,753 |
| XembifyImmune Globulin,gamma(Igg)klhw | 18 | $88,768 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 18 | $47,932 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 26 | $36,935 |
| OtrexupMethotrexate/Pf | 18 | $15,162 |
| Hydroxychloroquine Sulfate | 148 | $4,966 |
| Diclofenac Sodium | 62 | $4,788 |
| Cevimeline Hcl | 24 | $3,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $9,395 | $395,41556 claims |
| Grifols USA, LLCXembify, Gamunex-C | $99 | $136,70036 claims |
| GSKBenlysta | $248 | $106,60323 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $1,493 | $36,93526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 rheumatology providers in Georgia.
Other rheumatology in Lawrenceville
- Theresa Lawrence FordLawrenceville$2.9M
- Glenn ParrisLawrenceville$158K
- Samuel KimLawrenceville$24K
- Madhurika SamakurLawrenceville$23K
- Byung BanLawrenceville$19K
- Zohair AhmedLawrenceville$15K
- Wambui MachuaAtlanta$1.8M
- Brent FlickingerGainesville$1.6M
- James MossellTifton$1.6M
- Roel QuerubinMarietta$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.